Aaron Lyss, MBA, of Tennessee Oncology, discusses ways that clinicians and patients can employ the most cost- and treatment-effective measures, clinical trials, and incident learning systems.
Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings from a population-based study, which showed that many patients believe they had no choice about whether or not to receive radioactive iodine, even though it often does not improve survival. There is a need, she says, for better shared decision-making (Abstract 159).
Simron Singh, MD, MPH, of Sunnybrook Health Sciences Centre, discusses initial results of his data on a new patient experience measurement strategy used at Cancer Care Ontario.
Lalan S. Wilfong, MD, of Texas Oncology, discusses reducing the use of a white blood cell growth factor treatment in advanced and incurable solid tumors for patients treated at a community oncology practice.
Douglas W. Blayney, MD, of Stanford University, and winner of the Joseph V. Simone Award for Excellence, summarizes his talk on the expense of cancer care and how we can reduce costs while maintaining safety and high value for people with cancer.
Jeremy Warner, MD, of Vanderbilt-Ingram Cancer Center, discusses the ways in which patient navigators affect cancer care and how patients benefit.
